Get the Stockscreener App
104.75
0.26%
-0.27
After Hours:
106.80
2.05
+1.96%
Nuvalent Inc stock is traded at $104.75, with a volume of 619.06K.
It is down -0.26% in the last 24 hours and up +6.96% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$105.02
Open:
$105.02
24h Volume:
619.06K
Relative Volume:
1.14
Market Cap:
$8.24B
Revenue:
-
Net Income/Loss:
$-425.38M
P/E Ratio:
-17.90
EPS:
-5.8504
Net Cash Flow:
$-275.21M
1W Performance:
-0.28%
1M Performance:
+6.96%
6M Performance:
+16.86%
1Y Performance:
+47.99%
1-Day Range:
$103.84
$106.73
1-Week Range:
$99.78
$107.14
52-Week Range:
$63.55
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.75 | 8.26B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Wells Fargo | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent (NUVL) CSO Pelish sells $323k in shares By Investing.com - Investing.com India
Nuvalent (NUVL) CSO Pelish sells $323k in shares - Investing.com
Nuvalent (NUVL) CSO Pelish exercises options, sells 3,093 shares under plan - Stock Titan
(NUVL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Portfolio Update: Is Nuvalent Inc in a consolidation phase2026 Market Mood & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What Nuvalent (NUVL)'s FDA NDA Filing for Neladalkib in ALK-Positive NSCLC Means For Shareholders - simplywall.st
Nuvalent CEO Sells Over $3 Million in Stock - National Today
Nuvalent (NUVL) CEO trades 30K shares after option exercises - Stock Titan
Wedbush Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Nuvalent Submits NDA for Neladalkib in ALK+ NSCLC After TKIs - Oncology Nursing News
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $142 - Moomoo
Nuvalent Announces Submission of New Drug Application to FDA for - GuruFocus
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC - The Malaysian Reserve
Nuvalent Files FDA Application for Lung Cancer Therapy - TipRanks
Nuvalent Submits New Drug Application to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer - Minichart
Nuvalent submits new drug application to FDA for neladalkib in advanced lung cancer - Investing.com
Nuvalent Announces Submission Of New Drug Application To FDA For Neladalkib In Tki Pre-Treated Advanced Alk-Positive Nsclc - TradingView — Track All Markets
Nuvalent (NUVL) submits FDA New Drug Application for neladalkib in ALK+ lung cancer - Stock Titan
Aberdeen Group plc Increases Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
NUVL PE Ratio & Valuation, Is NUVL Overvalued - Intellectia AI
Nuvalent CFO Sells $1.2M in Shares - National Today
Nuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 11,430 Shares - MarketBeat
Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Nuvalent Insider Sold Shares Worth $537,943, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan - Stock Titan
Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $135 - moomoo.com
Price-Driven Insight from (NUVL) for Rule-Based Strategy - Stock Traders Daily
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch - Investing.com Australia
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch By Investing.com - Investing.com South Africa
22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL) - Stock Titan
Nuvalent Insider Sold Shares Worth $542,991, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1 - Stock Titan
Nuvalent Initiated at Overweight by Wells Fargo - Moomoo
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential By Investing.com - in.investing.com
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential - Investing.com India
Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Nuvalent at Overweight With $116 Price Target - marketscreener.com
Wells Fargo Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $116 - Moomoo
Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43% - Traders Union
Weekly Trades: Should I set a stop loss on Nuvalent IncQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Nuvalent (NUVL) ownership listed as 0 - Stock Titan
Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades - stocktitan.net
S&P 500 Futures Drop In Premarket Trading; Nuvalent, Figure Tech Solns Lead - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan
ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight - Barchart.com
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):